Nowadays, the immunotherapy approach with anti-PD1/PD-L1 antibodies for mCRC has demonstrated efficacy only in MMRd/MSI tumor subgroups but no in MMRp/MSS tumors. This evidence concerns the gene CD274 and neoplasm.